• CML: perceived relapse risk a key driver of TKI discontinuation

    Findings highlight need for improved decision support.

  • AACR 2019—Gilteritinib improves survival in FLT3-mutated AML

    Data from the phase 3 ADMIRAL trial led to U.S. regulatory approval.

  • B-cell precursor ALL: inotuzumab ozogamicin tops standard therapy

    Nearly 4 times as many patients went directly to HSCT.

  • CML: which tyrosine kinase inhibitor is safest?

    Study compares bosutinib, dasatinib, imatinib, nilotinib, ponatinib, and radotinib.

  • AML: pazopanib demonstrates limited efficacy in phase 2 study

    No significant reduction in BM microvessel density.

  • CLL: venetoclax-obinutuzumab induces deep, durable response

    Almost all patients responded, regardless of treatment line.

  • Elderly AML: intensive chemotherapy, decitabine offer similar OS

    Cytogenetic profile may help identify IC candidates.

  • CLL: broadening the scope of CAR T-cell therapy

    New studies involve combination regimens, multitargeted cells.

  • R/R Ph- B-cell ALL: study identifies the 3 components of "cure"

    Cure may be considered at 2-3 years off treatment.

  • NICE decision on blinatumomab for ALL in remission with MRD ≥0.1%

    Blinatumomab for acute lymphoblastic leukaemia in first or second complete remission with minimal residual disease of at least 0.1%

  • Pediatric CML: are adult data driving TKI discontinuation?

    STOP IMAPED shows low probability of sustained DMR.

  • R/R CLL: ibrutinib yields sustained PFS benefit in RESONATE

    Responses continued to deepen over time.

  • FN in AL/MDS: doripenem found noninferior to meropenem in RCT

    Both drugs demonstrated a favorable safety profile.

  • sAML: underlying MPN tied to inferior post-transplant survival

    Significant increase in relapse in CMML and MPN.

  • Load more